Group 1 - The company held the second supervisory board's seventh (temporary) meeting on November 11, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [2][3][5] - The supervisory board approved the adjustment of the proposed investment amount for fundraising projects due to the actual net fundraising amount being lower than planned, ensuring no harm to the company or shareholders' interests [3][4][56] - The board also approved the use of temporarily idle fundraising funds for cash management, which is expected to enhance fund utilization efficiency and increase company revenue [7][8][44] Group 2 - The company announced the first temporary shareholders' meeting for 2025, scheduled for November 28, 2025, with a combination of on-site and online voting [17][21][29] - The meeting will discuss previously disclosed proposals, including special resolutions and voting procedures for shareholders [21][22][24] Group 3 - The company plans to use up to RMB 900 million of temporarily idle fundraising funds for cash management, focusing on high-security, liquid financial products [31][33][36] - The cash management aims to improve fund utilization efficiency while ensuring that it does not affect the implementation of fundraising projects [41][44][46] Group 4 - The company intends to use its own funds to pay for fundraising project expenses and subsequently replace them with equivalent amounts from the fundraising account, ensuring operational efficiency [61][64][67] - This approach is designed to comply with the principle of using fundraising funds specifically for their intended purpose and will not affect the normal operation of fundraising projects [67][69][72]
广州必贝特医药股份有限公司